Cunningham Kent Douglas
Known title: Chief Executive OfficerCIK: 0002097408
Associated companies
Transaction History
| SRXH | ▲ Buy | Grant | 63 | $50K | 3/16/2026 | View on chart |
| SRXH | ▲ Buy | Grant | 200,000 | $78K | 12/3/2025 | View on chart |
| SRXH | ▲ Buy | Grant | 44,464 | $15K | 9/26/2025 | View on chart |
| SRXH | ▲ Buy | Grant | 231,193 | $93K | 8/25/2025 | View on chart |
| SRXH | ▲ Buy | Grant | 84,906 | $135K | 4/25/2025 | View on chart |
| SRXH | ▲ Buy | Grant | 71,770 | $150K | 4/24/2025 | View on chart |
| SRXH | ▲ Buy | Grant | 22,727 | $95K | 6/26/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
SRX Global liquidates two investments, adds Onconetix stake
SRX Global informed shareholders that it is liquidating two portfolio investments. The company also announced a new investment in Onconetix, a Nasdaq‑listed firm. These actions change the composition of SRX's holdings and could influence future cash flows. The stock is currently near its $1.57 support level.
SRX Global liquidates two investments, adds Onconetix stake. SRX Global informed shareholders that it is liquidating two portfolio investments. The company also announced a new investment in Onconetix, a Nasdaq‑listed firm. These actions change the composition of SRX's holdings and could influence future cash flows. The stock is currently near its $1.57 support level.